ATC Group: L01XX62 Ivosidenib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XX62 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XX Other antineoplastic agents
5 L01XX62

Active ingredients in L01XX62

Active Ingredient Description

Ivosidenib is an inhibitor of the mutant IDH1 enzyme. Mutant IDH1 converts alpha- ketoglutarate (αKG) to 2-hydroxyglutarate (2-HG) which blocks cellular differentiation and promotes tumorigenesis in both hematologic and non-hematologic malignancies. The mechanism of action of ivosidenib beyond its ability to reduce 2-HG and restore cellular differentiation is not fully understood across indications.

Related product monographs

Title Information Source Document Type  
TIBSOVO Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TIBSOVO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.